Physician profile
Scott Friedstrom
NPI 1679538698
$14,758.36
in general payments reported to CMS, 2019-2025
15 companies · $69.17 in 2025
The $69.17 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,090 · 2020: $1,232 · 2021: $75.18 · 2022: $690 · 2023: $4,583 · 2024: $2,020 · 2025: $69.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,100 · Food and Beverage: $1,500 · Education: $71.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,100.00 |
| Food and Beverage | $1,499.55 |
| Education | $71.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,283.56 | 2019-2020 | |
| Abbvie INC. | $5,639.36 | 2021-2025 | |
| Viiv Healthcare Company | $460.86 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $390.98 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $177.35 | 2022-2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $151.46 | 2021-2024 | Recarbrio, Zerbaxa, Dificid |
| Bioventus LLC | $141.46 | 2022 | |
| Smith+Nephew, INC. | $128.59 | 2023 | Stravix, Grafix Pl |
| Insmed, INC. | $104.39 | 2022-2023 | Arikayce |
| Melinta Therapeutics, LLC | $94.59 | 2022-2025 | Kimyrsa, Rezzayo, Vabomere |
| Astellas Pharma US INC | $71.99 | 2023 | |
| Pfizer INC. | $40.18 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $38.90 | 2024 | |
| La Jolla Pharmaceutical Company | $20.42 | 2024 | Xerava |
| Novo Nordisk INC | $14.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Friedstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.